dopamine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
dopaminergic agents dopamine derivatives used as cardiac stimulant/antihypertensives/diuretics	947	51-61-6

Description:

Molecule

Description

Molfile Inchi Smiles Synonyms: dopamine oxytyramine dopamin dophamine hydroxytyramin dopamine hydrochloride dopamine HCl

One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action. Molecular weight: 153.18 Formula: C8H11NO2 CLOGP: 0.17 LIPINSKI: 0 HAC: 3 HDO: 3 TPSA: 66.48 ALOGS: -1.31 ROTB: 2 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Drug dosage:

Dose	Unit	Route
0.50	g	P

ADMET properties:

Property	Value	Reference
MRTD (Maximum Recommended Therapeutic Daily Dose)	470 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Hosey CM, Chan R, Benet LZ
Vd (Volume of distribution)	0.74 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	65.90 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.87 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	0.42 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Feb. 25, 1974	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Renal injury	166.07	23.88	59	6479	9482	46670042
Hypotension	155.08	23.88	176	6362	232413	46447111
Multiple organ dysfunction syndrome	144.57	23.88	90	6448	51620	46627904
Fear	135.86	23.88	59	6479	16113	46663411
Renal failure	133.15	23.88	117	6421	113477	46566047
Cardiac arrest	117.85	23.88	99	6439	90300	46589224
Renal impairment	117.17	23.88	91	6447	74281	46605243
Injury	116.42	23.88	74	6464	43953	46635571
Anhedonia	114.71	23.88	46	6492	10289	46669235
Unevaluable event	94.06	23.88	66	6472	46109	46633415
Emotional distress	89.67	23.88	55	6483	30652	46648872
Cardiogenic shock	85.44	23.88	43	6495	16341	46663183
Shock	73.83	23.88	43	6495	21802	46657722
Diabetes insipidus	68.25	23.88	21	6517	2153	46677371
Renal ischaemia	62.80	23.88	15	6523	588	46678936
Bradycardia	55.90	23.88	57	6481	66241	46613283
Blood pressure decreased	53.46	23.88	52	6486	57107	46622417
PCO2 increased	51.91	23.88	15	6523	1239	46678285
Blood bicarbonate decreased	50.77	23.88	18	6520	2867	46676657
Blood pH decreased	48.55	23.88	17	6521	2610	46676914
Oxygen saturation abnormal	47.99	23.88	17	6521	2701	46676823
PO2 increased	47.55	23.88	13	6525	877	46678647
Acute kidney injury	43.04	23.88	99	6439	235756	46443768
Metabolic acidosis	41.44	23.88	38	6500	38742	46640782
Fatigue	41.19	23.88	17	6521	608680	46070844
Stress	41.05	23.88	43	6495	51508	46628016
Ventricular tachycardia	41.04	23.88	27	6511	16940	46662584
Septic shock	36.94	23.88	43	6495	57850	46621674
Cardiac failure	34.64	23.88	49	6489	79899	46599625
Haemodynamic instability	33.72	23.88	18	6520	7707	46671817
Status epilepticus	33.21	23.88	22	6516	13957	46665567
Activated partial thromboplastin time prolonged	32.76	23.88	17	6521	6872	46672652
Platelet count decreased	31.65	23.88	53	6485	99971	46579553
Disseminated intravascular coagulation	31.48	23.88	24	6514	18981	46660543
Pulmonary haemorrhage	30.78	23.88	16	6522	6489	46673035
Arthralgia	30.30	23.88	7	6531	364596	46314928
Electroencephalogram abnormal	29.24	23.88	13	6525	3741	46675783
Sepsis	29.18	23.88	61	6477	135953	46543571
Left ventricular dysfunction	28.97	23.88	18	6520	10237	46669287
Foetal death	28.97	23.88	17	6521	8726	46670798
Anxiety	28.44	23.88	72	6466	181885	46497639
Clonus	28.20	23.88	13	6525	4067	46675457
Intraventricular haemorrhage neonatal	27.68	23.88	6	6532	151	46679373
Blood urea increased	27.38	23.88	25	6513	25327	46654197
Enzyme induction	26.95	23.88	5	6533	55	46679469
Hepatic failure	26.81	23.88	28	6510	33388	46646136
Malaise	26.27	23.88	7	6531	331225	46348299
Respiratory failure	25.78	23.88	47	6491	94769	46584755
Anuria	24.79	23.88	17	6521	11414	46668110
Headache	24.23	23.88	19	6519	478333	46201191

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Fear	225.20	19.01	91	8005	10734	29933648
Renal injury	191.56	19.01	83	8013	11646	29932736
Injury	189.89	19.01	100	7996	21631	29922751
Multiple organ dysfunction syndrome	184.78	19.01	146	7950	63341	29881041
Anhedonia	162.55	19.01	67	8029	8302	29936080
Unevaluable event	147.20	19.01	97	7999	31688	29912694
Renal failure	133.76	19.01	169	7927	128797	29815585
Emotional distress	116.60	19.01	65	8031	15700	29928682
Stress	109.10	19.01	68	8028	20167	29924215
Renal impairment	83.40	19.01	108	7988	84076	29860306
Hypotension	79.34	19.01	170	7926	200395	29743987
Cardiogenic shock	67.34	19.01	47	8049	16814	29927568
Anxiety	64.73	19.01	99	7997	89772	29854610
Shock	56.69	19.01	48	8048	22811	29921571
Disseminated intravascular coagulation	51.81	19.01	45	8051	22126	29922256
Blood pressure decreased	50.66	19.01	63	8033	47012	29897370
Ventricular fibrillation	48.63	19.01	37	8059	15101	29929281
Hypertrophic cardiomyopathy	46.55	19.01	15	8081	918	29943464
Blood urea increased	43.77	19.01	48	8048	31333	29913049
Neonatal disorder	42.60	19.01	14	8082	912	29943470
Incision site pain	42.15	19.01	17	8079	1987	29942395
Cardiac arrest	40.38	19.01	82	8014	92768	29851614
Ventricular tachycardia	39.51	19.01	40	8056	23822	29920560
Distributive shock	38.95	19.01	12	8084	634	29943748
Torsade de pointes	38.30	19.01	24	8072	7166	29937216
Fatigue	37.62	19.01	20	8076	320653	29623729
Pain	36.60	19.01	116	7980	172525	29771857
Lymphocyte count decreased	35.37	19.01	34	8062	19021	29925361
Pulmonary haemorrhage	34.75	19.01	25	8071	9367	29935015
Metabolic acidosis	32.32	19.01	45	8051	37416	29906966
Dizziness	31.68	19.01	7	8089	194902	29749480
Septic shock	31.05	19.01	59	8037	63548	29880834
Urine output decreased	29.53	19.01	23	8073	9706	29934676
Headache	28.73	19.01	7	8089	182299	29762083
Neutrophil count increased	27.79	19.01	27	8069	15296	29929086
Arthralgia	26.26	19.01	3	8093	135788	29808594
Respiratory failure	25.41	19.01	72	8024	100570	29843812
Anuria	24.21	19.01	21	8075	10295	29934087
Asthenia	24.19	19.01	15	8081	221275	29723107
Bradycardia	23.99	19.01	54	8042	65472	29878910
Cardiac failure	23.36	19.01	62	8034	83356	29861026
Acidosis	22.24	19.01	20	8076	10281	29934101
Intraventricular haemorrhage neonatal	22.02	19.01	6	8090	204	29944178
Nausea	21.91	19.01	29	8067	296928	29647454
Red blood cells urine positive	21.75	19.01	10	8086	1607	29942775
Oliguria	21.32	19.01	17	8079	7422	29936960
Sepsis	21.25	19.01	87	8009	146308	29798074
Toxic epidermal necrolysis	20.88	19.01	25	8071	17915	29926467
Left ventricle outflow tract obstruction	19.49	19.01	5	8091	134	29944248

Pharmacologic Action:

Source	Code	Description
ATC	C01CA04	CARDIOVASCULAR SYSTEM CARDIAC THERAPY CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES Adrenergic and dopaminergic agents
FDA CS	M0003647	Catecholamines
FDA EPC	N0000175570	Catecholamine
MeSH PA	D002316	Cardiotonic Agents
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D015259	Dopamine Agents
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D020011	Protective Agents
MeSH PA	D013566	Sympathomimetics
CHEBI has role	CHEBI:35522	beta-adrenergic receptor agonist
CHEBI has role	CHEBI:35524	sympathomimetic
CHEBI has role	CHEBI:38147	cardiotonic drugs
CHEBI has role	CHEBI:48560	dopamine agents
CHEBI has role	CHEBI:75771	mus musculus metabolite
CHEBI has role	CHEBI:76971	e.coli metabolites
CHEBI has role	CHEBI:77746	h. sapiens metabolites

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Low cardiac output syndrome	indication	44088000
Low blood pressure	indication	45007003
Decompensated cardiac failure	indication	195111005
Sinus bradycardia	off-label use	49710005
Acute nephropathy	off-label use	58574008
Tachyarrhythmia	contraindication	6285003
Hypovolemia	contraindication	28560003
Ventricular arrhythmia	contraindication	44103008
Acidosis	contraindication	51387008
Pheochromocytoma	contraindication	302835009
Hypoxia	contraindication	389086002
Occlusive Vascular Disease	contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.96	acidic
pKa2	12.98	acidic
pKa3	10.61	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Beta-1 adrenergic receptor	GPCR	P08588	ADRB1_HUMAN	AGONIST	Ki	5		WOMBAT-PK	CHEMBL
D(1B) dopamine receptor	GPCR	P21918	DRD5_HUMAN	AGONIST	Ki	9		WOMBAT-PK
Beta-2 adrenergic receptor	GPCR	P07550	ADRB2_HUMAN		Kd	4.19		CHEMBL
Melatonin receptor type 1A	GPCR	P48039	MTR1A_HUMAN		Ki	5.15		CHEMBL
Melatonin receptor type 1B	GPCR	P49286	MTR1B_HUMAN		Ki	5.04		CHEMBL
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN		Ki	5.19		CHEMBL
5-hydroxytryptamine receptor 1A	GPCR	P08908	5HT1A_HUMAN		Ki	5.08		PDSP
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN	AGONIST	Ki	9		WOMBAT-PK
D(2) dopamine receptor	GPCR	P14416	DRD2_HUMAN	AGONIST	Ki	9		WOMBAT-PK
D(1A) dopamine receptor	GPCR	P21728	DRD1_HUMAN	AGONIST	Ki	9		WOMBAT-PK
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN		IC50	8.18		WOMBAT-PK
Trace amine-associated receptor 1	GPCR	Q96RJ0	TAAR1_HUMAN		Ki	6.37		WOMBAT-PK
Dopamine beta-hydroxylase	Enzyme	P09172	DOPO_HUMAN		Km	3		WOMBAT-PK
FAD-linked sulfhydryl oxidase ALR	Enzyme	P55789	ALR_HUMAN		AC50	5.85		CHEMBL
Lysine-specific demethylase 4E	Enzyme	B2RXH2	KDM4E_HUMAN		IC50	5.52		CHEMBL
D(4) dopamine receptor	GPCR	P21917	DRD4_HUMAN	AGONIST	Ki	9		WOMBAT-PK
Dopamine receptor	GPCR		DRD1_BOVIN DRD2_BOVIN		IC50	8.43		CHEMBL
Sodium-dependent dopamine transporter	Transporter		SC6A3_RAT		IC50	6.70		CHEMBL
Adenylate cyclase	Enzyme		ADCY2_RAT ADCY3_RAT ADCY4_RAT ADCY5_RAT ADCY6_RAT ADCY8_RAT D4A3N4_RAT Q8CFM9_RAT		EC50	5.46		CHEMBL
D(1A) dopamine receptor	GPCR		DRD1_BOVIN		Ki	8.15		CHEMBL
Beta-1 adrenergic receptor	GPCR		ADRB1_RAT		Ki	5		CHEMBL
D(4) dopamine receptor	GPCR		DRD4_RAT		EC50	8.62		CHEMBL
Dopamine receptor	GPCR		DRD1_RAT DRD2_RAT DRD3_RAT DRD4_RAT DRD5_RAT		IC50	5.27		CHEMBL
Adrenergic receptor alpha-2	GPCR		ADA2A_RAT ADA2B_RAT ADA2C_RAT		Ki	7.24		CHEMBL
Adrenergic receptor alpha-1	GPCR		ADA1A_RAT ADA1B_RAT ADA1D_RAT		Ki	4.85		CHEMBL
D(2) dopamine receptor	GPCR		DRD2_BOVIN		Ki	8.74		CHEMBL
Beta-2 adrenergic receptor	GPCR		ADRB2_CANFA		Ki	4.30		CHEMBL
D(1A) dopamine receptor	GPCR		DRD1_RAT		Ki	6.82		CHEMBL
D(2) dopamine receptor	GPCR		DRD2_RAT		Ki	8.35		CHEMBL
D(3) dopamine receptor	GPCR		DRD3_RAT		Ki	7.96		CHEMBL
Opioid receptor	GPCR		OPRD_RAT OPRK_RAT OPRM_RAT SGMR1_RAT		IC50	5.52		CHEMBL
Adenosine A2b receptor	GPCR		AA2BR_RAT		Ki	6.01		CHEMBL
M18 aspartyl aminopeptidase	Unclassified		Q8I2J3_PLAF7		IC50	5.70		CHEMBL

External reference:

ID	Source
4019733	VUID
N0000147825	NUI
D00633	KEGG_DRUG
62-31-7	SECONDARY_CAS_RN
4018656	VANDF
4019733	VANDF
C0013030	UMLSCUI
CHEBI:18243	CHEBI
LDP	PDB_CHEM_ID
CHEMBL59	ChEMBL_ID
CHEMBL1557	ChEMBL_ID
DB00988	DRUGBANK_ID
D004298	MESH_DESCRIPTOR_UI
681	PUBCHEM_CID
940	IUPHAR_LIGAND_ID
2417	INN_ID
VTD58H1Z2X	UNII
3628	RXNORM
3090	MMSL
4632	MMSL
6641	MMSL
d00216	MMSL
001787	NDDF
004721	NDDF
16257000	SNOMEDCT_US
412383006	SNOMEDCT_US
59187003	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Dopamine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9252	INJECTION	40 mg	INTRAVENOUS	ANDA	16 sections
Dopamine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9253	INJECTION	80 mg	INTRAVENOUS	ANDA	16 sections
Dopamine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9254	INJECTION	40 mg	INTRAVENOUS	ANDA	16 sections
Dopamine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9255	INJECTION	80 mg	INTRAVENOUS	ANDA	16 sections
MYOCARD-DX	HUMAN PRESCRIPTION DRUG LABEL	2	0264-1840	INJECTION	80 mg	INTRAVENOUS	EXPORT ONLY	20 sections
MYOCARD-DX	HUMAN PRESCRIPTION DRUG LABEL	2	0264-1880	INJECTION	800 mg	INTRAVENOUS	EXPORT ONLY	20 sections
Dopamine Hydrochloride and Dextrose	HUMAN PRESCRIPTION DRUG LABEL	1	0338-1005	INJECTION, SOLUTION	80 mg	INTRAVENOUS	NDA	22 sections
Dopamine Hydrochloride and Dextrose	HUMAN PRESCRIPTION DRUG LABEL	1	0338-1007	INJECTION, SOLUTION	160 mg	INTRAVENOUS	NDA	22 sections
Dopamine Hydrochloride and Dextrose	HUMAN PRESCRIPTION DRUG LABEL	1	0338-1009	INJECTION, SOLUTION	320 mg	INTRAVENOUS	NDA	22 sections
DOPamine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0409-5820	INJECTION, SOLUTION, CONCENTRATE	40 mg	INTRAVENOUS	NDA	17 sections
Dopamine Hydrochloride in Dextrose	HUMAN PRESCRIPTION DRUG LABEL	1	0409-7808	INJECTION, SOLUTION	0.80 mg	INTRAVENOUS	NDA	25 sections
Dopamine Hydrochloride in Dextrose	HUMAN PRESCRIPTION DRUG LABEL	1	0409-7809	INJECTION, SOLUTION	1.60 mg	INTRAVENOUS	NDA	25 sections
Dopamine Hydrochloride in Dextrose	HUMAN PRESCRIPTION DRUG LABEL	1	0409-7810	INJECTION, SOLUTION	3.20 mg	INTRAVENOUS	NDA	25 sections
DOPamine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0409-9104	INJECTION, SOLUTION, CONCENTRATE	40 mg	INTRAVENOUS	NDA	17 sections
DOPAMINE HCI	HUMAN PRESCRIPTION DRUG LABEL	1	51662-1220	INJECTION, SOLUTION, CONCENTRATE	40 mg	INTRAVENOUS	NDA	12 sections
DOPAMINE HCI	HUMAN PRESCRIPTION DRUG LABEL	1	51662-1291	INJECTION, SOLUTION, CONCENTRATE	40 mg	INTRAVENOUS	NDA	12 sections
DOPAMINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	51662-1316	INJECTION, SOLUTION	1.60 mg	INTRAVENOUS	NDA	13 sections
DOPAMINE HCI IN 5% DEXTROSE	HUMAN PRESCRIPTION DRUG LABEL	1	51662-1458	INJECTION, SOLUTION	1.60 mg	INTRAVENOUS	NDA	13 sections
Dopamine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	52584-104	INJECTION, SOLUTION, CONCENTRATE	40 mg	INTRAVENOUS	NDA	11 sections
Dopamine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	52584-820	INJECTION, SOLUTION, CONCENTRATE	40 mg	INTRAVENOUS	NDA	11 sections
DOPamine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	71872-7066	INJECTION, SOLUTION, CONCENTRATE	40 mg	INTRAVENOUS	NDA	17 sections